Immunomodulatory Effect of the Topical Ophthalmic Janus Kinase Inhibitor Tofacitinib (CP-690,550) in Patients with Dry Eye Disease
Ophthalmology, 05/21/2012
Clinical Article
Huang JF et al. – Topical ophthalmic tofacitinib may act as an immunomodulator in patients with dry eye disease. Treatment for 8 weeks showed a promising reduction of conjunctival cell surface human leukocyte antigen DR–1 expression and tear levels of proinflammatory cytokines and inflammation markers.



